about
Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828.Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14.Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trialFeasibility of economic analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare data.Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer.Patient-reported outcomes and survivorship in radiation oncology: overcoming the consEconomic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases.Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.The role of licensed nursing personnel in radiation oncology part B: integrating the ambulatory care nursing conceptual framework.Impact of gender, partner status, and race on locoregional failure and overall survival in head and neck cancer patients in three radiation therapy oncology group trials.The RTOG Outcomes Model: economic end points and measures.Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancerNurse Practitioners' attitudes about cancer clinical trials and willingness to recommend research participationFour-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.Stamp test delivers message on erectile dysfunction after high-dose intensity-modulated radiotherapy for prostate cancer.Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.Prostate cancer risk assessment program: a 10-year update of cancer detection.TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.The role of licensed nursing personnel in radiation oncology part a: results of a descriptive study.Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.Prostate cancer early detection program recruitment methods and show rates in men at high risk.Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy.The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials.Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10)
P50
Q30809152-68CCE591-06F7-4E38-8F8A-6CB08C06FFE3Q33248555-9C4646CA-CAF6-44EA-AEE8-6B7A6C976823Q33446356-0BCAF145-A448-404F-957D-FDA32840AF74Q33578849-68C9EA30-051A-4477-9A45-3A129BCF42A5Q33956838-FBB7CF68-C31A-4C8C-8012-F650D98E1B98Q34124311-C9C3909D-823E-4933-8FC7-E97395668500Q34138298-1EE96681-12AA-4C76-85B8-BA1F13097502Q34315605-7DB64863-3B1D-45E4-B30A-C0F3C01830AFQ35039956-E83FB24B-33FB-4D0A-9C04-6B1A3BEE4F1AQ35207399-89165819-80D0-4761-8DA5-01390B107293Q35688143-BD7DEA6C-BCC2-47D9-82CB-C58A3AB3D8CAQ36166224-195B994E-7C24-4A04-A43D-928B657FCAA1Q36761294-FF1961A7-C9D0-4C9E-A643-7E5CEB5D9E2CQ36767280-9F1FD2B9-96D9-487E-B000-020677201BA6Q37187732-8C660F96-5F50-4521-93E0-F33193F660C6Q39593619-B2043E15-F9BC-407C-9C21-BB205D2B3DDEQ39645828-FE955CCF-5A29-4845-A3FC-853FCCEE989BQ39813420-695FAD5A-B5CA-4FE4-AA1E-E58EE4062507Q40207325-35C10691-59AB-4780-9B77-1D653CE67516Q40611906-09E72FA8-FB1F-41E6-AC77-E293EEBF6E63Q41981580-8763BA58-E471-4FCD-B8E7-6A0ED9AECD87Q42582024-8F608CF5-0D24-48D8-890B-73B71160332CQ43168667-0ACA7810-948D-449A-8324-EFC2C0798135Q43720688-398148A9-6E68-4706-AAE6-15A4A67A0376Q44037457-C275AA55-128E-4C7E-A84C-5B6D73DF1C66Q46831870-D121C4A5-F5AE-4C53-9A1C-4879B3EA2D2AQ53198957-9EC705E0-3310-4019-B153-E573101699CCQ54141723-CBAD1CCD-4074-4D9C-9BBF-5DD02A212423Q57695961-82C34AAA-AF0E-46E8-AB1D-41F735638677
P50
name
Deborah Watkins-Bruner
@ast
Deborah Watkins-Bruner
@en
Deborah Watkins-Bruner
@nl
type
label
Deborah Watkins-Bruner
@ast
Deborah Watkins-Bruner
@en
Deborah Watkins-Bruner
@nl
prefLabel
Deborah Watkins-Bruner
@ast
Deborah Watkins-Bruner
@en
Deborah Watkins-Bruner
@nl